Home Semiconductor & Electronics Electronic Components SGLT2 Inhibitors Market

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Ipragliflozin, Sotagliflozin, Others), By Indication (Type 2 Diabetes, Cardiovascular, Chronic Kidney Disease, Weight Management, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 23, 2025 | Author: Debashree B | Format: | Report Code: SR7660DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. SGLT2 Inhibitors Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Canagliflozin
    2. Dapagliflozin
    3. Empagliflozin
    4. Ertugliflozin
    5. Ipragliflozin
    6. Sotagliflozin
    7. Others
  2. SGLT2 Inhibitors Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Type 2 Diabetes
    2. Cardiovascular
    3. Chronic Kidney Disease 
    4. Weight Management
    5. Others
  3. SGLT2 Inhibitors Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Online Pharmacies
  4. Regional SGLT2 Inhibitors Market
    1. North America
      1. North America SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. North America SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. North America SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.S. SGLT2 Inhibitors Market
        1. U.S. SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. U.S. SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. U.S. SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      5. Canada SGLT2 Inhibitors Market
        1. Canada SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Canada SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Canada SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
    2. Europe
      1. Europe SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. Europe SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. Europe SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. U.K. SGLT2 Inhibitors Market
        1. U.K. SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. U.K. SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. U.K. SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      5. Germany SGLT2 Inhibitors Market
        1. Germany SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Germany SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Germany SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      6. France SGLT2 Inhibitors Market
        1. France SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. France SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. France SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      7. Spain SGLT2 Inhibitors Market
        1. Spain SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Spain SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Spain SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      8. Italy SGLT2 Inhibitors Market
        1. Italy SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Italy SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Italy SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      9. Russia SGLT2 Inhibitors Market
        1. Russia SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Russia SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Russia SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      10. Nordic SGLT2 Inhibitors Market
        1. Nordic SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Nordic SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Nordic SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      11. Benelux SGLT2 Inhibitors Market
        1. Benelux SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Benelux SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Benelux SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      12. Rest of Europe SGLT2 Inhibitors Market
        1. Rest of Europe SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Rest of Europe SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Rest of Europe SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
    3. APAC
      1. APAC SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. APAC SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. APAC SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. China SGLT2 Inhibitors Market
        1. China SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. China SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. China SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      5. Korea SGLT2 Inhibitors Market
        1. Korea SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Korea SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Korea SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      6. Japan SGLT2 Inhibitors Market
        1. Japan SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Japan SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Japan SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      7. India SGLT2 Inhibitors Market
        1. India SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. India SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. India SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      8. Australia SGLT2 Inhibitors Market
        1. Australia SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Australia SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Australia SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      9. Taiwan SGLT2 Inhibitors Market
        1. Taiwan SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Taiwan SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Taiwan SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      10. South East Asia SGLT2 Inhibitors Market
        1. South East Asia SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. South East Asia SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. South East Asia SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      11. Rest of Asia-Pacific SGLT2 Inhibitors Market
        1. Rest of Asia-Pacific SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Rest of Asia-Pacific SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Rest of Asia-Pacific SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. Middle East and Africa SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. Middle East and Africa SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. UAE SGLT2 Inhibitors Market
        1. UAE SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. UAE SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. UAE SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      5. Turkey SGLT2 Inhibitors Market
        1. Turkey SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Turkey SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Turkey SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      6. Saudi Arabia SGLT2 Inhibitors Market
        1. Saudi Arabia SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Saudi Arabia SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Saudi Arabia SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      7. South Africa SGLT2 Inhibitors Market
        1. South Africa SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. South Africa SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. South Africa SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      8. Egypt SGLT2 Inhibitors Market
        1. Egypt SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Egypt SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Egypt SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      9. Nigeria SGLT2 Inhibitors Market
        1. Nigeria SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Nigeria SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Nigeria SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      10. Rest of MEA SGLT2 Inhibitors Market
        1. Rest of MEA SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Rest of MEA SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Rest of MEA SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
    5. LATAM
      1. LATAM SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Canagliflozin
        2. Dapagliflozin
        3. Empagliflozin
        4. Ertugliflozin
        5. Ipragliflozin
        6. Sotagliflozin
        7. Others
      2. LATAM SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Type 2 Diabetes
        2. Cardiovascular
        3. Chronic Kidney Disease 
        4. Weight Management
        5. Others
      3. LATAM SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Online Pharmacies
      4. Brazil SGLT2 Inhibitors Market
        1. Brazil SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Brazil SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Brazil SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      5. Mexico SGLT2 Inhibitors Market
        1. Mexico SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Mexico SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Mexico SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      6. Argentina SGLT2 Inhibitors Market
        1. Argentina SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Argentina SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Argentina SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      7. Chile SGLT2 Inhibitors Market
        1. Chile SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Chile SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Chile SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      8. Colombia SGLT2 Inhibitors Market
        1. Colombia SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Colombia SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Colombia SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
      9. Rest of LATAM SGLT2 Inhibitors Market
        1. Rest of LATAM SGLT2 Inhibitors Market By Drug 2022-2034 (USD MILLION/ Units)
          1. Canagliflozin
          2. Dapagliflozin
          3. Empagliflozin
          4. Ertugliflozin
          5. Ipragliflozin
          6. Sotagliflozin
          7. Others
        2. Rest of LATAM SGLT2 Inhibitors Market By Indication 2022-2034 (USD MILLION/ Units)
          1. Type 2 Diabetes
          2. Cardiovascular
          3. Chronic Kidney Disease 
          4. Weight Management
          5. Others
        3. Rest of LATAM SGLT2 Inhibitors Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacies
          2. Drug Stores & Retail Pharmacies
          3. Online Pharmacies
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.